Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q2 FY21 results · Jul–Sep 2020
Alkem Laboratories reported revenue from operations of ₹2,362.80 crore (up 4.4% from Q2 FY20) and net profit of ₹481.51 crore (up 26.5% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,362.80 | 2,264.03 | +4.4% | 2,003.49 | +17.9% |
| Other income | 35.54 | 31.42 | +13.1% | 43.50 | −18.3% |
| Total income | 2,398.34 | 2,295.45 | +4.5% | 2,046.99 | +17.2% |
| Profit before tax | 547.75 | 409.86 | +33.6% | 492.75 | +11.2% |
| Net profit for the period | 481.51 | 380.52 | +26.5% | 423.19 | +13.8% |
| Attributable to shareholders of the company | 472.06 | 370.85 | +27.3% | 422.01 | +11.9% |
| EPS, basic (₹) | 39.48 | 31.02 | +27.3% | 35.30 | +11.9% |
| Net margin (%) | 20.4 | 16.8 | 21.1 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,984.10 | 1,894.65 | +4.7% | 1,550.85 | +27.9% |
| Other income | 24.84 | 30.59 | −18.8% | 32.45 | −23.5% |
| Total income | 2,008.94 | 1,925.24 | +4.3% | 1,583.30 | +26.9% |
| Profit before tax | 552.73 | 465.29 | +18.8% | 479.13 | +15.4% |
| Net profit for the period | 495.20 | 434.02 | +14.1% | 426.16 | +16.2% |
| EPS, basic (₹) | 41.42 | 36.30 | +14.1% | 35.64 | +16.2% |
| Net margin (%) | 25.0 | 22.9 | 27.5 |
Consolidated
- Filed with BSE
- 06 Nov 2020, 17:54 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2020, 17:54 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE